Trial reportHuman vaccines & immunotherapeutics2013
17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.
Trial report in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area
An Exploratory, Pilot Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review on Yellow Fever Vaccine and Adverse Events.Global health, epidemiology and genomics · 2026Pooled it
- Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.The New England journal of medicine · 2025Trial
- Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity.PLoS neglected tropical diseases · 2025Trial
- Low-Dose Yellow Fever Vaccine in Adults in Africa.The New England journal of medicine · 2025Trial
- Trial
- Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023Trial
- Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.Frontiers in immunology · 2019Trial
- Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.Memorias do Instituto Oswaldo Cruz · 2015Trial
- Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline.BMC infectious diseases · 2014Trial
- Yellow Fever Vaccination in an Individual with Confirmed Egg Protein Allergy: A Case Report.Vaccines · 2026Article
- Proxy immunization enabling yellow fever vaccination after thymectomy.NPJ vaccines · 2026Article
- Immunoprevention and immunomodulation of yellow fever: A scoping review of global and Latin American evidence.PloS one · 2026Article
- Mechanistic yellow fever modelling under climate change in Brazil and beyond: Information gaps and future steps.Wellcome open research · 2025Article
- A Fast One-Step RT-qPCR to Quantify Yellow Fever Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Neutralization Tests for Quantification of Specific Antibodies Against Yellow Fever Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Investigating the association between yellow fever vaccination and symptomatic acute Zika virus infection: a case-control study.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Article
- Exploring Iguape Virus-A Lesser-Known Orthoflavivirus.Viruses · 2024Review
- Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.Journal of virology · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo verify if the Bio-Manguinhos 17DD yellow fever vaccine (17DD-YFV) used in lower doses is as immunogenic and safe as the current formulation.
resultsDoses from 27,476 IU to 587 IU induced similar seroconversion rates and neutralizing antibodies geometric mean titers (GMTs). Immunity of those who seroconverted to YF was maintained for 10 mo. Reactogenicity was low for all groups.
methodsYoung and healthy adult males (n = 900) were recruited and randomized into 6 groups, to receive de-escalating doses of 17DD-YFV, from 27,476 IU to 31 IU. Blood samples were collected before vaccination (for neutralization tests to yellow fever, serology for dengue and clinical chemistry), 3 to 7 d after vaccination (for viremia and clinical chemistry) and 30 d after vaccination (for new yellow fever serology and clinical chemistry). Adverse events diaries were filled out by volunteers during 10 d after vaccination. Volunteers were retested for yellow fever and dengue antibodies 10 mo later. Seropositivity for dengue was found in 87.6% of volunteers before vaccination, but this had no significant influence on conclusions.
conclusionIn young healthy adults Bio-Manguinhos/Fiocruz yellow fever vaccine can be used in much lower doses than usual. INTERNATIONAL REGISTER: ISRCTN 38082350.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.